Edwards Lifesciences
About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Employees: 15,800
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
122% more call options, than puts
Call options by funds: $586M | Put options by funds: $264M
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
30% more first-time investments, than exits
New positions opened: 184 | Existing positions closed: 141
19% more capital invested
Capital invested by funds: $31.4B [Q3] → $37.5B (+$6.11B) [Q4]
6.29% more ownership
Funds ownership: 78.78% [Q3] → 85.06% (+6.29%) [Q4]
2% more funds holding
Funds holding: 1,180 [Q3] → 1,204 (+24) [Q4]
30% less repeat investments, than reductions
Existing positions increased: 347 | Existing positions reduced: 496
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$71
1%
downside
Avg. target
$79
10%
upside
High target
$90
26%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
Truist Securities Richard Newitter 54% 1-year accuracy 26 / 48 met price target | 5%upside $75 | Hold Maintained | 11 Apr 2025 |
Barclays Matt Miksic 44% 1-year accuracy 18 / 41 met price target | 26%upside $90 | Overweight Maintained | 13 Feb 2025 |
Canaccord Genuity William Plovanic 37% 1-year accuracy 18 / 49 met price target | 1%downside $71 | Hold Maintained | 13 Feb 2025 |
RBC Capital Shagun Singh 36% 1-year accuracy 24 / 66 met price target | 19%upside $85 | Outperform Reiterated | 12 Feb 2025 |
Piper Sandler Adam Maeder 43% 1-year accuracy 6 / 14 met price target | 2%upside $73 | Neutral Maintained | 12 Feb 2025 |
Financial journalist opinion
Based on 7 articles about EW published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neutral
Business Wire
1 day ago
Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d.
Positive
Zacks Investment Research
2 days ago
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Neutral
Business Wire
3 days ago
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L.
Neutral
Business Wire
5 days ago
Edwards SAPIEN M3 Receives CE Mark, Becoming World's First Transfemoral Transcatheter Mitral Valve Replacement System
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company's SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement ther.
Neutral
Business Wire
2 weeks ago
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology's (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredict.
Positive
Seeking Alpha
4 weeks ago
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic.
Neutral
Business Wire
1 month ago
Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor
SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operation.
Neutral
Business Wire
1 month ago
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life.
Positive
Zacks Investment Research
1 month ago
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
Charts implemented using Lightweight Charts™